EPAM Systems, a software services developing company, announced the launch of its EPAM Cloud Pipeline solution, which aims to accelerate drug discovery clinical research.
The application is available on Amazon and Google Cloud, and it will now be made available for purchase on the Microsoft Azure platform, an online marketplace created by Microsoft for buying and selling of software services.
EPAM Cloud Pipeline will be open-source, and will utilize machine learning capabilities, allowing scientists to build and run customized scripts and workflows required to support genomics analysis, modeling, and simulation operations during clinical research.
According to EPAM, the software will function as a combination of a cloud application (leveraging Azure’s computing and storage resources) and on-premises software installed on the users’ computers.
Greg Killian, head of Life Sciences business unit of EPAM, commented that the service’s intuitive interface is expected to help scientists manage the ‘constantly changing’ demands in analytics and modeling, without requiring specialized IT skills.
According to Killian, the software regards researchers whose studies require significant computational power and storage capacity, aiming to help them save valuable time and lower the costs of their research.
On his side, Sajan Parihar, senior director of the Microsoft Azure, explained that the platform will provide EPAM with the opportunity to reach more healthcare and life sciences customers.
